A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]) to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease

Trial Profile

A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]) to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2009

At a glance

  • Drugs CERE 120 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Ceregene
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top